Company news

PepGen Inc. news in 2026

PepGen Inc.'s news releases, calls and decks from 2026, newest first.

View company

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 6, 2026

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

August 6, 2026

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

May 21, 2026

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 12, 2026

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

March 29, 2026

PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

March 3, 2026

PepGen Announces Regulatory Updates on FREEDOM2

March 3, 2026

PepGen to Participate in the Leerink Global Healthcare Conference

March 2, 2026

Decks in 2026